GPRC5D-Targeted Therapies in Relapsed Multiple Myeloma: Real-World Results and Community Practice Challenges

home / training-academy / gprc5d-targeted-therapies-in-relapsed-multiple-myeloma-real-world-results-and-community-practice

Salman Fazal, MD; Yvonne Efebera, MD; Sumit Madan, MD, Ruemu Birhiray, MD, discuss how evaluating real-world efficacy and safety outcomes of GPRC5D-targeted therapies, along with identifying practical challenges and considerations, can guide the implementation of bispecifics in community practices.

4 KOLs are featured in this series.

EP. 1: GPRC5D-Targeted Therapies in Relapsed Multiple Myeloma

Salman Fazal, MD ;Yvonne Efebera, MD ;Sumit Madan, MD ;Ruemu Birhiray, MD
September 27th 2024

Panelists discuss how their clinical experience with GPRC5D bispecific therapies has been limited or nonexistent due to the novelty of these treatments in multiple myeloma.

4 KOLs are featured in this series.

EP. 2: Real-World Efficacy of GPRC5D Bispecifics vs Clinical Trials

Salman Fazal, MD ;Yvonne Efebera, MD ;Sumit Madan, MD ;Ruemu Birhiray, MD
September 27th 2024

Panelists discuss how GPRC5D bispecific therapies have shown promising efficacy in real-world relapsed/refractory multiple myeloma patients.